Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its…
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell…
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
Media Release IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the…
BOSTON, MA / ACCESSWIRE / August 13, 2024 / Colorectal cancer, a serious condition affecting the colon or rectum, is…
Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program…
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin…
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with…
Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline resectable pancreatic cancerPresented positive…